KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …

KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …

KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …

KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …

KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …

In this Letter, the statement:'The authors declare competing financial interests: details
accompany the full-text HTML version of the paper at www. nature. com/nature.'was missing …

The mechanism of action of three different allosteric MEK inhibitors that target the MAP
kinase pathway is investigated, and their efficacy is shown to be explained by the distinct …

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven
cancers | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

The mechanism of action of three different allosteric MEK inhibitors that target the MAP
kinase pathway is investigated, and their efficacy is shown to be explained by the distinct …

KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of
the MAPK pathway. As these tumours represent an area of high unmet medical need …